Thirty-one days. That’s the window the FDA just added.
The original comment deadline for the FDA’s AI clinical trial pilot program Request for Information was May 29, 2026, one day from today. The agency published a Federal Register extension notice on May 28, 2026, shifting the deadline to June 29, according to the Federal Register notice (91 FR 23100 references the original April 29 RFI; the extension carries a separate citation). For organizations that hadn’t finalized comments, this extension is immediately actionable.
The pilot program examines AI use in early-phase clinical trial design and oversight, a sector where the stakes of AI deployment are high and the regulatory framework is still forming. According to the Federal Register notice, the agency’s RFI explores how AI can support drug sponsors in designing and managing early-phase trials, with a particular focus on where human oversight requirements remain non-negotiable. The program’s scope, per the original RFI, is explicitly exploratory: the FDA is soliciting input before committing to a framework, not implementing one already decided.
Who This Affects
One specific claim in the Wire’s reporting requires qualified framing: the NIST AI Risk Management Framework is reported to be explicitly referenced in the notice as an alignment basis for AI governance in clinical settings, according to the Federal Register notice. We haven’t accessed the specific notice text to confirm this directly, so organizations submitting comments should verify the NIST alignment claim against the published notice before relying on it structurally.
Why the comment window matters. The FDA isn’t finalizing rules here, it’s gathering structured input to inform how it will govern AI in clinical trial contexts. That’s the rarer opportunity. Established guidance frameworks are difficult to revise after publication; an active RFI is an open door. Drug sponsors with existing AI clinical workflows, medical device developers with embedded AI components, and health tech companies developing trial management tools all have concrete operational experience the FDA needs. The comment record shapes whatever framework follows.
Verification
Partial Federal Register domain-level citation (91 FR 23100 for original RFI); extension notice has separate citation not yet available NIST AI RMF alignment claim is per Wire characterization of notice text, verify directly against Federal Register publication before citing in comment submissionsWhat to watch
the FDA’s final framework response to this RFI, expected to draw from comment submissions in shaping formal guidance on AI in clinical trials. There’s no published timeline for that guidance yet, but the comment extension suggests the agency is taking the input process seriously. Submitters should watch the Federal Register docket for any further extensions or preliminary response publications.
The broader pattern is consistent with what sector regulators are doing across AI governance: gathering information through formal processes before committing to mandatory structures. The FDA AI clinical trial RFI sits alongside the EU AI Act’s Annex III deferrals and the White House’s shift to voluntary frameworks as evidence that regulators at every level are choosing deliberate pacing over rapid enforcement. For organizations with AI clinical trial operations, the June 29 deadline is a concrete action date. Whether to submit is a strategic decision; the window to do so is now confirmed open.